Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B-YOND extension study.
Pasi KJ, Fischer K, Ragni M, Kulkarni R, Ozelo MC, Mahlangu J, Shapiro A, P'Ng S, Chambost H, Nolan B, Bennett C, Matsushita T, Winding B, Fruebis J, Yuan H, Rudin D, Oldenburg J. Pasi KJ, et al. Among authors: rudin d. Haemophilia. 2020 Nov;26(6):e262-e271. doi: 10.1111/hae.14036. Epub 2020 Jun 4. Haemophilia. 2020. PMID: 32497409
Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study.
Nolan B, Mahlangu J, Pabinger I, Young G, Konkle BA, Barnes C, Nogami K, Santagostino E, Pasi KJ, Khoo L, Winding B, Yuan H, Fruebis J, Rudin D, Oldenburg J. Nolan B, et al. Among authors: rudin d. Haemophilia. 2020 May;26(3):494-502. doi: 10.1111/hae.13953. Epub 2020 Mar 30. Haemophilia. 2020. PMID: 32227570 Free PMC article.
First-in-human, randomized dose-escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF-06480605 in healthy subjects.
Banfield C, Rudin D, Bhattacharya I, Goteti K, Li G, Hassan-Zahraee M, Brown LS, Hung KE, Pawlak S, Lepsy C. Banfield C, et al. Among authors: rudin d. Br J Clin Pharmacol. 2020 Apr;86(4):812-824. doi: 10.1111/bcp.14187. Epub 2020 Jan 28. Br J Clin Pharmacol. 2020. PMID: 31758576 Free PMC article. Clinical Trial.
In vitro and in vivo metabolism of psilocybin's active metabolite psilocin.
Thomann J, Kolaczynska KE, Stoeckmann OV, Rudin D, Vizeli P, Hoener MC, Pryce CR, Vollenweider FX, Liechti ME, Duthaler U. Thomann J, et al. Among authors: rudin d. Front Pharmacol. 2024 Apr 29;15:1391689. doi: 10.3389/fphar.2024.1391689. eCollection 2024. Front Pharmacol. 2024. PMID: 38741590 Free PMC article.
Seasonal influenza vaccine performance and the potential benefits of mRNA vaccines.
Russell CA, Fouchier RAM, Ghaswalla P, Park Y, Vicic N, Ananworanich J, Nachbagauer R, Rudin D. Russell CA, et al. Among authors: rudin d. Hum Vaccin Immunother. 2024 Dec 31;20(1):2336357. doi: 10.1080/21645515.2024.2336357. Epub 2024 Apr 15. Hum Vaccin Immunother. 2024. PMID: 38619079 Free PMC article. Review.
Pharmacokinetics-Based Pediatric Dose Evaluation and Optimization Using Saliva - A Case Study.
Anliker-Ort M, Rodieux F, Ziesenitz VC, Atkinson A, Bielicki JA, Erb TO, Gürtler N, Holland-Cunz S, Duthaler U, Rudin D, Haschke M, van den Anker J, Pfister M, Gotta V. Anliker-Ort M, et al. Among authors: rudin d. J Clin Pharmacol. 2024 Mar 18. doi: 10.1002/jcph.2428. Online ahead of print. J Clin Pharmacol. 2024. PMID: 38497339 Free article.
83 results